Argenx price target raised to $600 from $595 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Argenx to $600 from $595 and keeps an Overweight rating on the shares. The analyst increased near-term Vyvgart estimates following a 149 neurologist survey, which the firm views as bullish. The shift toward earlier-line Vyvgart adoption is well underway, and projected uptake of the Vyvgart Hytrulo format is “impressive” and indicates less cannibalization of IV Vyvgart than expected, the analyst tells investors in a research note.